Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
17 studies found for:    ( Phentermine AND Topiramate ) [TREATMENT] AND Obesity [DISEASE]
Show Display Options
Rank Status Study
1 Completed
Has Results
Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
Condition: Obesity
Interventions: Drug: Phentermine-Topiramate ER;   Drug: Placebo
2 Withdrawn Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity
Conditions: Obesity;   Diabetes Mellitus
Interventions: Other: Behavioral and Drug;   Other: Behavioral
3 Completed Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
Condition: Obesity
Interventions: Drug: topiramate;   Drug: phentermine
4 Completed
Has Results
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: Placebo matched phentermine/topiramate
5 Completed
Has Results
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: topiramate;   Drug: phentermine
6 Active, not recruiting A Toolbox Approach to Obesity Treatment in Primary Care
Condition: Obesity
Interventions: Behavioral: Commercial weight loss program;   Behavioral: Colorado Weigh;   Dietary Supplement: Meal replacements;   Drug: Obesity pharmacotherapy;   Behavioral: Recreation center passes
7 Completed
Has Results
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Condition: Obesity
Interventions: Drug: Qsymia;   Drug: Placebo
8 Completed
Has Results
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: Placebo
9 Recruiting DAPA, EQW, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Conditions: Polycystic Ovary Syndrome;   Obesity
Interventions: Drug: Exenatide once weekly (EQW );   Drug: Dapagliflozin (DAPA);   Drug: EQW plus DAPA;   Drug: Dapagliflozin plus Glucophage (MET ER);   Drug: Phentermine /Topiramate (PHEN/ TRP) ER
10 Completed A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
Condition: Obesity
Intervention: Drug: Metformin, VI-0521, Sitagliptan, Probenecid
11 Active, not recruiting Qsymia as an Adjunct to Surgical Therapy in the Superobese
Conditions: Obesity;   Metabolic Surgery;   Weight Loss;   Bariatric Surgery Procedures
Intervention: Drug: Phentermine/topiramate
12 Completed Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
Condition: Binge Eating Disorder
Intervention: Drug: PHEN/TPM ER (Qsymia®)
13 Completed
Has Results
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
Condition: Sleep Apnea
Interventions: Drug: VI-0521;   Drug: placebo
14 Completed
Has Results
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: VI-0521;   Drug: Placebo
15 Completed
Has Results
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
Conditions: Obesity;   Type 2 Diabetes
Intervention: Drug: VI-0521
16 Completed A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
Conditions: Pediatric Obesity;   Childhood Obesity
Interventions: Drug: Placebo;   Drug: VI-0521 Mid Dose;   Drug: VI-0521 Top Dose
17 Completed
Has Results
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
Conditions: Overweight;   Obesity
Interventions: Drug: VI-0521;   Drug: Placebo;   Other: Alcohol;   Other: alcohol placebo

Study has passed its completion date and status has not been verified in more than two years.